26th Annual Biotech in Europe Forum

Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Eleva’s disruptive moss-based technology platform enables GMP-scale manufacturing of human proteins with tremendous therapeutic potential that have been too challenging to manufacture using other approaches. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. The lead program, CPV-104 recombinant human complement Factor H, is in Phase 1b testing to treat C3 Glomerulopathy (C3G). An intravitreal formulation of the candidate is in late preclinical development to treat dry AMD. The company’s aGal (RPV-001) program has completed a positive Phase 1b single-dose clinical trial to treat Fabry disease.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies for serious brain and retinal diseases.

Lead program, GAL-101 (eye drops), is in a Phase 2 trial for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration (dAMD). An oral formulation of GAL-101 has successfully completed Phase 1 testing and shown to be safe, well tolerated, and effectively crosses the blood-brain barrier. Target engagement could be shown. Phase 2 trials in Alzheimer’s (oral) and glaucoma (eye drops) are planned. A next-generation compound, GAL-301, is in pre-clinical testing.
Galimedix is looking for crossover financing to progress GAL-101 to clinical proof of concept in Alzheimer´s disease and to advance its earlier-stage programs ahead of a planned US IPO.

Galimedix has signed a licensing and equity deal with Théa Open Innovation for co-development and commercial rights to GAL-101 in ophthalmology, excluding APAC and is pursuing additional regional partnerships.

Recent highlights include the successful completion of the first-in-human study of the oral version of GAL-101, data presented at CTAD, and the ongoing Phase 2 eDREAM trial in GA, with LPI anticipated this year.

Micreos is a pharmaceutical biotech based in Zug, Switzerland that discovers & develops recombinant engineered endolysin proteins that act on disease pathways in Dermatology, Oncology and Infectious disease conditions.

Our business model is focused on drug discovery & early drug development (up until clinical proof of concept) with subsequent M&A at an asset level for Phase-III development and global commercialization.
The experienced leadership team consists of a complementary blend of seasoned leaders from both big-pharma and smaller-biotech. The team has the experience and ‘knows-what-it-takes’ to bring molecules all the way through successful discovery, development, registration, reimbursement & commercialization.

Curlim is a late stage preclinical  biotech company developing an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules. First applications target hereditary peripheral neuropathies and neurodegenerative diseases.

Lead indication is CMT1a, the most common hereditary neuropathy, causing lifelong progressive motor disorders beginning in childhood.

At present, there is no pharmacological treatment for nervous disorders known as peripheral neuropathies. Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy (HPN). Therapeutic strategies remain very limited and do not address the cause of the disease, but mainly its symptoms. This lack of pharmacological treatment is particularly dramatic in the case of hereditary peripheral neuropathies, as they are diffuse and often manifest very early in the patient's life and persist throughout their lifetime.

Our solution has been developed by LImoges labs (neuro and sciences) and consists of a Platform technology. The platform is a novel cationic beta-cyclodextrin crystalline-nanocrystal (B-CD/CNC) nanocarrier system for improved solubility, bioavailability, and cellular penetration of APIs.

Our compund CLM001 Targets Oxidative Stress, Heavily Implicated in Peripheral Neuropathies.

CLM001 obtained unprecedented and spectacular therapeutic effects demonstrated on 2 CMT1A animal models showing anti-inflammatory, antioxidant, and remyelinating effects, with no toxicity signals.

CLM001 shows a significant rescue in the nerve function. When treated for a total of 12 weeks, CLM001 significantly improved balance/speed and increased the nerve conductivity.

In parallel, Primary and secondary modes of action have been characterized.

From a regulatory point of view, Orphan Drug Designation has been granted both by EMA and by FDA.

CMC is finalized and next development stage will be the launch of pre-clinical toxicology study.

ExpreS2ion is a clinical-stage biotechnology company turning precise protein engineering into immunotherapies for cancer and infectious diseases.

Our lead asset, ES2B-C001, is an active immunotherapy for HER2-positive and HER2-low breast cancer. Rather than delivering an antibody, it trains a patient's own immune system to produce a sustained anti-HER2 response. In our first-in-human Phase I trial, anti-HER2 antibody responses have been observed in all nine evaluable patients to date, with titres rising across dosing visits and holding at follow-up, and no safety signals of concern. The highest dose cohort opened in May 2026, with primary readout expected end-2026 and Phase II targeted for mid-2027.

ES2B-C001 is built on the ExpreS2™ platform, our proprietary protein expression technology used across more than 500 recombinant protein and virus-like particle projects. Proteins made on the platform have been evaluated in clinical programmes worldwide, including partnered Phase III studies that met their primary endpoints.

ExpreS2ion develops VLP-based vaccines with AdaptVac ApS, in which it holds a 34% stake, and is listed on Nasdaq First North Growth Market (EXPRS2).

OxSonics is a game changing MedTech company, spun out from the University of Oxford, a Focused Ultrasound Center of Excellence. The company has developed a novel, breakthrough ultrasound-mediated drug delivery platform to significantly improve delivery of anti-cancer drugs into the target tumor site. Located in Oxford, the team is made of 7 people whose 50% are PhD.

SonoTran® is a platform comprising a proprietary ultrasound engine and Sonosensitive Particles which are co-administered and systemically infused alongside anti-cancer drugs.

OxSonics has recached a major inflection point with the completed In first‑in‑human mCRC trial , SonoTran® improved response rates (86% vs 67%), with complete responses in 4/7 patients without any device-related safety issues reported.

kezbio is developing a drug discovery platform for unstructured and intrinsically disordered proteins (undruggables).

We integrate fragment-based approaches with activity-based-probes and fast chemoenzymatic biocatalysis for fast and lean discovery.

Nerai develops in vivo CRISPR editors that reach mutations others cannot. A single editor treats many rare diseases, compounding small, individually unprofitable orphan indications into one scalable, blockbuster-scale asset. Our vision: no disease stays too rare to be worth a cure.